Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Current Deferred Revenue (2020 - 2026)

Cytek Biosciences filings provide 6 years of Current Deferred Revenue readings, the most recent being $28.5 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 11.82% to $28.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.5 million, a 11.82% increase, with the full-year FY2025 number at $28.5 million, up 11.82% from a year prior.
  • Current Deferred Revenue hit $28.5 million in Q4 2025 for Cytek Biosciences, down from $28.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $29.6 million in Q2 2023 to a low of $4.7 million in Q2 2021.
  • Median Current Deferred Revenue over the past 5 years was $23.0 million (2024), compared with a mean of $20.3 million.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 46.23% in 2021 and later skyrocketed 241.0% in 2022.
  • Cytek Biosciences' Current Deferred Revenue stood at $7.1 million in 2021, then surged by 83.39% to $13.0 million in 2022, then surged by 74.77% to $22.7 million in 2023, then grew by 12.32% to $25.5 million in 2024, then increased by 11.82% to $28.5 million in 2025.
  • The last three reported values for Current Deferred Revenue were $28.5 million (Q4 2025), $28.7 million (Q3 2025), and $28.1 million (Q2 2025) per Business Quant data.